Compare Modine Manufacturing Company (MOD) vs Regeneron Pharmaceuticals Inc (REGN) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Modine Manufacturing Company vs Regeneron Pharmaceuticals Inc — how do they compare? Modine Manufacturing Company trades at $198.81 (market cap $10.15B), while Regeneron Pharmaceuticals Inc trades at $799.06 (market cap $83.19B). The key difference: Regeneron Pharmaceuticals Inc is far larger — about 8.2× Modine Manufacturing Company's market cap, and Regeneron Pharmaceuticals Inc pays a 0.47% dividend while Modine Manufacturing Company pays none. Which is the better fit depends on your goals.
| MOD | REGN | |
|---|---|---|
Market Cap | $10.15B | $83.19B |
Sector | Technology | Health |
52-Week High | $306.89 | $812.27 |
52-Week Low | $119.68 | $545.94 |
Enterprise Value | $10.58B | $77.90B |
Dividend Yield | — | 0.47% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Modine Manufacturing (MOD) trades at $195.60, up 1.6% on the day, with a bearish technical signal but strong fundamental growth driven by data center demand. The stock shows stretched valuation with a P/E of 71.27, yet has beaten earnings estimates for three consecutive quarters. Recent news highlights surging data center sales but also margin pressure and supply-chain constraints.
Outlook is mixed: robust revenue growth and a $319 consensus price target suggest upside, but high valuation, margin compression, and technical weakness pose risks. Investors should weigh strong analyst buy ratings against execution challenges in a competitive thermal management market.
Regeneron Pharmaceuticals (REGN) trades at $784.36, up 1.59% today, with a bullish technical signal from moving averages but overbought RSI readings. The company shows strong profitability with a net income margin of 27.86% and has beaten EPS estimates in recent quarters. However, multiple class-action lawsuits filed in August 2026 allege inadequate clinical-trial risk disclosures, creating investor uncertainty amid solid financial performance.
Outlook remains supported by earnings momentum and analyst buy ratings, but legal risks and high valuation multiples pose near-term headwinds. Investment opportunity hinges on legal resolution and sustained drug pipeline success, while risks include trial setbacks and regulatory scrutiny.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Modine Manufacturing Company
Modine Manufacturing Company is a global leader in thermal management technology and solutions. The company engineers, manufactures, and markets heat transfer products for a wide range of applications across the automotive, commercial, industrial, and HVAC (heating, ventilation, and air conditioning) markets. Modine's products include engine cooling systems, heat exchangers, and ventilation systems, providing critical thermal solutions for vehicles, data centers, and various equipment worldwide.
Read more on MOD →About Regeneron Pharmaceuticals Inc
Regeneron Pharmaceuticals discovers, develops, and commercializes products that fight eye disease, cardiovascular disease, cancer, and inflammation. The company has several marketed products, including Eylea, approved for wet age-related macular degeneration and other eye diseases
Read more on REGN →
